Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell Broaddus

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Oncotarget|May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I programGenevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget|September 10, 2019
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2017
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular SubtypesJonathan M Loree, Allan A L Pereira, Michael Lam, et al.
Molecular Cancer Therapeutics|December 15, 2017
Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine CancerYan Huang, Wei Hu, Jie Huang, et al.
Oncotarget|April 19, 2017
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
JCO Precision Oncology|July 24, 2018
Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast CancerFunda Meric-Bernstam, Xiaofeng Zheng, Maryam Shariati, et al.
Gynecologic Oncology|February 10, 2021
Clinical significance of homologous recombination deficiency score testing in endometrial CancerJean H Siedel, Kari L Ring, Wei Hu, et al.
Journal of the National Cancer Institute|April 12, 2015
A decision support framework for genomically informed investigational cancer therapyFunda Meric-Bernstam, Amber Johnson, Vijaykumar Holla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancerJanos L Tanyi, Yutaka Hasegawa, Ruth Lapushin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2014
Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to DasatinibJie Huang, Wei Hu, Justin Bottsford-Miller, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Oncotarget|May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I programGenevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget|September 10, 2019
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2017
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular SubtypesJonathan M Loree, Allan A L Pereira, Michael Lam, et al.
Molecular Cancer Therapeutics|December 15, 2017
Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine CancerYan Huang, Wei Hu, Jie Huang, et al.
Oncotarget|April 19, 2017
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
JCO Precision Oncology|July 24, 2018
Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast CancerFunda Meric-Bernstam, Xiaofeng Zheng, Maryam Shariati, et al.
Gynecologic Oncology|February 10, 2021
Clinical significance of homologous recombination deficiency score testing in endometrial CancerJean H Siedel, Kari L Ring, Wei Hu, et al.
Journal of the National Cancer Institute|April 12, 2015
A decision support framework for genomically informed investigational cancer therapyFunda Meric-Bernstam, Amber Johnson, Vijaykumar Holla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancerJanos L Tanyi, Yutaka Hasegawa, Ruth Lapushin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2014
Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to DasatinibJie Huang, Wei Hu, Justin Bottsford-Miller, et al.
Pageof 10